Mitochondrial damage and neuroinflammation belong to two of the most important pathological factors in multiple neurological disorders. However, the effect of mitochondrial damage of microglia on microglial activation under pathological conditions has remained unclear. In our current study, we used BV2 microglia as a cellular model to determine the effects of mitochondrial electron transport chain (ETC) inhibitors on LPS-induced inflammatory responses of microglia. We found that all of the three mitochondrial ETC inhibitors, including rotenone, sodium azide and antimycin A, significantly inhibited LPS-induced inflammatory responses of the microglia, assessed by determinations of the protein or mRNA levels of IL-1, IL-6, TNF- iNOS and COX2Nuclear translocation of NF-B p65 subunit does not appear to play an important role in the mitochondrial ETC inhibition-produced suppression of microglial activation. Instead, our study found that the mitochondrial ETC inhibitors significantly attenuated not only the LPS-induced increase in the TREM1 levels -an amplifier of inflammatory process, but also the LPS-induced increase in the ratio of phosphorylated STAT3 / STAT3. In summary, our study has suggested that mitochondrial ETC inhibition of microglia can lead to suppression of LPS-induced microglial activation, which may be mediated by the inhibitory effects of mitochondrial ETC inhibition on the LPS-induced increases in the level of TREM1 and the ratio of p-STAT3 / STAT3. These findings have provided valuable information for elucidating the relationships between mitochondrial damage and neuroinflammation in multiple neurological diseases.
Introduction
Mitochondrial damage (1) (2) (3) and neuroinflammation (4, 5) belong to two of the most important pathological factors in multiple neurological diseases such as Parkinson's disease, Alzheimer's disease and brain ischemia. Mitochondria is the main source of cellular energy by coupling the oxidation of pyruvate and fatty acids to the production of adenosine triphosphate (ATP) by the mitochondrial ETC (6) . The mitochondrial damage in the neurological disorders can produce major pathological alterations by causing both impaired energy metabolism and increased oxidative stress (7) .
Neuroinflammation is a main host defense response to injury (4, 8) . Numerous studies have indicated that neuroinflammation is a critical pathological factor in multiple neurological disorders (4, 5, 9) , although neuroinflammation can also produce beneficial effects under certain conditions (10) . Excessive activation of microglia -the major immune cells in the brain -leads to the production of multiple pro-inflammatory factors, which play a key role in neuroinflammation (11, 12) . Since inhibition of the detrimental effects of neuroinflammation has been an important therapeutic strategy for multiple neurological diseases, it is of great significance to determine the key factors that modulate neuroinflammation in the brain under multiple pathological conditions. The major goal of our current study was to determine the effects of mitochondrial ETC inhibition on neuroinflammation by using BV2 microglia -a widely used microglia model -as a cellular model. It is established that mitochondrial damage of such brain cell types as neurons can lead to necrosis, resulting in increased neuroinflammation. However, the effect of mitochondrial damage of microglia on microglial activation has remained unclear. Our current study has shown that mitochondrial ETC inhibition of microglia can profoundly suppress neuroinflammation in LPS-treated BV2 microglia, which could be mediated by the inhibitory effects of mitochondrial ETC inhibition on the LPS-induced increases in the levels of TREM1 and phosphorylated STAT3.
Materials and Methods

Reagents
Rotenone (45656), LPS (L2880) and NADH (N4505) were purchased from Sigma Aldrich (St Louis, MI, USA). Antimycin A (ab141904) was purchased from Abcam (Cambridge, USA). Sodium azide (DB0613) and primers were purchased from Sangon Biotech (Shanghai, China).
Cell Cultures
BV2 microglial cells were a gift from the Institute of Neurology, Ruijin Hospital (Shanghai, China). The cells were plated into 24-well or 12-well culture plates in Dulbecco's modified Eagle medium (HyClone, Logan, UT, United States) supplemented with 10% fetal bovine serum (Gibco, Carlsbad, CA, United States), 100 units/ml penicillin and 100 μg/ml streptomycin at 37 °C in a humidified incubator under 5% CO 2 .
Intracellular Lactate Dehydrogenase (LDH) Assay
Cell death was determined by measuring the intracellular lactate dehydrogenase (LDH) activity of the cells. In brief, cells were lysed for 20 min in lysing buffer containing 0.04% Triton X-100, 2 mM HEPES and 0.01% bovine serum albumin (pH 7.5). Then 50 μL cell lysates were mixed with 150 μL reaction buffer containing 0.34 mM NADH and 2.5 mM sodium pyruvate (pH 7.5). The changes of the A 340nm of the samples were monitored over 90 s. Percentage of cell death was calculated by normalizing the LDH values of samples to the LDH values of the lysates of control.
Nitric Oxide Assay
Nitric oxide (NO) production by BV2 microglia was assessed by determining the levels of nitrite accumulated in the culture media using Griess Reagent (Beyotime, Jiangsu, China). According to the manufacturer's protocols, 50 µl of culture media of BV2 cells was incubated with 50 µl of Griess reagent I, which was then mixed with 50 µl of Griess reagent II. The absorbance at 540 nm of the samples was assessed by a microplate reader (Synergy 2; Biotek, Winooski, VT, United States). The nitrite levels of the samples were normalized to the protein concentrations, which were determined by the Bicinchoninic Acid (BCA) assay. 
Realtime
Western Blot Assays
The cells were harvested and lysed in RIPA buffer (Millipore, Temecula, 
Statistical Analysis
Data were presented as mean ± SEM and analyzed by one way analysis of variance (ANOVA) followed by Student-Newman-Keuls post hoc test. P values less than 0.05 were considered statistically significant.
Results
Mitochondrial ETC inhibitors significantly suppressed LPS-induced increases in the pro-inflammatory factors in BV2 microglia
We used rotenone, sodium azide and antimycin A -three widely used mitochondrial ETC inhibitors (13, 14) -to produce inhibition of the mitochondrial ETC of BV2 microglia. The concentrations of rotenone, sodium azide and antimycin A used in our study were 100 nM, 2.5 mM, and 50 nM, respectively, since at these concentrations the mitochondrial ETC inhibitors did not significantly affect the survival of BV2 microglia (Supplementary Figures S1).
There are several hallmarks of microglial activation, including increased levels of NO and increased protein or mRNA levels of iNOS, COX2, IL-1, IL-6 and TNF- Our study found that 100 nM rotenone, 2.5 mM sodium azide and 50 nM antimycin A significantly attenuated the LPS-induced increases in the NO level of the cells (Figure 1a ). LPS treatment led to significant increases in the protein levels of iNOS and COX2 of the cells, which were also significantly attenuated by the mitochondrial ETC inhibitors (Figures 1b -1d ). We further found that the mitochondrial ETC inhibitors significantly suppressed the LPS-induced increases in the mRNA levels of IL-1, IL-6 and TNF-Figures 2a -2c.
The mitochondrial ETC inhibitors did not affect the nuclear translocation of NF-κB p65 subunit in the LPS-treated BV2 microglia
The nuclear factor NF-kB pathway is a well-established pro-inflammatory mediator (16) , which plays critical roles in numerous inflammatory responses (17, 18) .
We conducted Western blot assays to determine the effects of the mitochondrial ETC inhibitors on the nuclear translocation of NF-κB p65 subunit -the major index of NF-κB activation (19) , which did not indicate that the mitochondrial ETC inhibitors can significantly affect the nuclear translocation of NF-κB p65 subunit Figures 3a -3f.
Three mitochondrial ETC inhibitors significantly suppressed the LPS-induced increases in both the mRNA and protein levels of TREM1 in BV2 microglia
A number of studies have suggested that TREMs play important regulatory roles in inflammation (20) (21) (22) . We found that LPS treatment led to a significant increase in the mRNA level of TREM1, which was significantly attenuated by the three mitochondrial ETC inhibitors Figures 4aLPS treatment also led to a significant increase in the protein level of TREM1, which was attenuated by rotenone (Figure 4b ), sodium azide ( Figure 4c ) and antimycin A (Figure 4d) . Quantifications of the Western blot assays showed that the mitochondrial ETC inhibitors significantly suppressed the LPS-induced increase the protein levels of TREM1 in BV2 microglia Figures 4e -4g.
Mitochondrial ETC inhibitors significantly suppressed the LPS-induced increase in the ratio of phosphorylated STAT3 (p-STAT3) / STAT3 in BV2 microglia
Since the key downstream proteins in the TREM1 signaling pathway include STAT3, MAPK, and AKT, we conducted Western blot assays to determine the effects of the three mitochondrial ETC inhibitors on the ratios of p-STAT3 / STAT3, p-p38 / p38, p-ERK1/2 / ERK1/2, p-JNK / JNK and p-AKT /AKT in the LPS-treated BV2 microglia (Fig. 5a ). Of the five proteins, only the LPS-induced increase in the ratio of p-STAT3 / STAT3 was significantly suppressed by the mitochondrial ETC inhibitors Figures 5b -5f.
Discussion
The major findings of our current study include: First, mitochondrial ETC inhibition can lead to decreased level of neuroinflammation in LPS-treated BV2 microglia; second, nuclear translocation of NF-B p65 subunit does not play an important role in the mitochondrial ETC inhibition-produced suppression of microglial activation; third, mitochondrial ETC inhibition can decrease the LPS-induced increases in the levels of TREM1 in BV2 microglia; and fourth, mitochondrial ETC inhibition can suppress the LPS-induced increase in the ratio of p-STAT3 / STAT3 in BV2 microglia. These findings have provided novel information for elucidating the relationships between mitochondrial damage and neuroinflammation in multiple neurological disorders.
Mitochondrial damage and neuroinflammation belong to two most critical pathological factors in multiple neurological diseases. It is of significance to elucidate the relationship between these two pathological factors and expose the mechanisms underlying the relationship. However, the information regarding this relationship is highly insufficient. Our current study has shown that all of the three mitochondrial ETC inhibitors used in this study can significantly suppress the inflammatory responses in LPS-treated BV2 microglia. Our study has indicated that mitochondrial damage of microglia does not lead to increasing inflammatory responses in microglia.
Instead, it leads to suppression of inflammatory responses in microglia. However, it is noteworthy that evaluation on the general effect of mitochondrial damage on neuroinflammation should be conducted on a broad scale: The mitochondrial damage of such cell types as neurons and astrocytes can lead to necrosis of the cells, which is expected to enhance the level of neuroinflammation.
It has been reported that uncoupling protein-2 (UCP-2) can provide neuroprotective effects by preventing neuronal death after stroke or brain trauma, while the mechanisms have remained unclear (23) . Our study has provided a new line of information for accounting for the seemingly paradoxical finding: UCP-2 in microglia may lead to decreased microglial activation-based neuroinflammation by impairing microglial mitochondrial functions, resulting in the neuroprotective effect of UCP-2.
The transcriptional factors of NF-κB family play critical roles in inflammation and innate immunity (16, 24, 25) . However, our study did not find that the mitochondrial ETC inhibitors can affect the nuclear translocation of NF-κB p65 subunit. Instead, our current study has indicated that mitochondrial ETC inhibition can decrease the LPS-induced increase in the level of TREM1 in BV2 microglia, which could at least partially account for the mitochondrial inhibitor-produced suppression of LPS-induced microglial activation. The triggering receptors expressed on myeloid cells (TREMs) are members of the immunoglobulin-like superfamily of receptors. In humans, two similar proteins, TREM1 and TREM2 are encoded by two homologous genes (26, 27) . Accumulating evidence has indicated that TREM1 is an amplifier of the inflammatory process, while TREM2 has anti-inflammatory activity (22, 26, 28, 29) . Inhibition of TREM1 has shown to attenuate the inflammation in several animal models of diseases, such as fatty liver diseases, rheumatoid arthritis or pneumonia (28, 30, 31) . Our current study has shown that the three mitochondrial ETC inhibitors significantly decreased both the mRNA and protein levels of TREM1
in LPS-treated BV2 microglia, suggesting that the mitochondrial ETC inhibitor-produced suppression of the LPS-induced microglial activation results at least partially from its capacity to decrease the TREM1 level. However, it is warranted to further investigate the mechanisms underlying the capacity of the mitochondrial ETC inhibitors to decrease the TREM1 level.
We conducted studies to further determine if the mitochondrial ETC inhibitor can Among the STAT family, phosphorylation of STAT3 is closely associated with inflammatory response (36) . It was reported that TREM1 expression in splenic conventional dendritic cells was strongly up-regulated, which subsequently elicited the activation of STAT3 (37) . Inhibition of STAT3 signal pathway was also shown to prevent α-synuclein-induced neuroinflammation and LPS-induced chronic liver injury (38, 39) . Our current study has indicated that the mitochondrial ETC inhibitors can significantly decrease the ratio of p-STAT3 / STAT3 in the LPS-treated BV2 microglia.
Collectively, these pieces of information has suggested that the mitochondrial ETC inhibitors lead to suppression of LPS-induced microglial activation by decreasing the ratio of p-STAT3 / STAT3 that results from the mitochondrial ETC inhibitor-produced decrease in the TRME1 level. The data were pooled from three independent experiments. *, P < 0.05; **, P < 0.01; ***, P < 0.001. experiments. ***, P < 0.001.
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